Stockreport

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

Tiziana Life Sciences Ltd - Common Shares  (TLSA) 
PDF First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Pat [Read more]